You just read:

Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B

News provided by

Sangamo Therapeutics, Inc.

Dec 17, 2018, 08:00 ET